Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Department of Psychiatry, Neuropsychiatry Section, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 2Genetic Epidemiology Research Branch Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA
Список исп. литературыСкрыть список
1. Dominguez MD, Wichers M, Lieb R et al. Evidence that onset of clinical psychosis is an outcome of progressively more persistent subclinical psychotic experiences: an 8-year cohort study. Schizophr Bull 2011;37:84-93.
2. Kelleher I, Connor D, Clarke MC et al. Prevalence of psychotic symptoms in childhood and adolescence: a systematic review and meta-analysis of population-based studies. Psychol Med 2012;42:1857-63.
3. Linscott RJ, van Os J. An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: on the pathway from proneness to persistence to dimensional expression across mental disorders. Psychol Med 2013;43: 1133-49.
4. van Os J, Reininghaus U. Psychosis as a transdiagnostic and extended phenotype in the general population. World Psychiatry 2016;15:118-24.
5. Debbane M, Badoud D, Balanzin D et al. Broadly defined risk mental states during adolescence: disorganization mediates positive schizotypal expression. Schizophr Res 2013;147:153-6.
6. Kline E, Schiffman J. Psychosis risk screening: a systematic review. Schizophr Res 2014;158:11-8.
7. Zammit S, Kounali D, Cannon M et al. Psychotic experiences and psychotic disorders at age 18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort study. Am J Psychiatry 2013;170:742-50.
8. Yung AR, Lin A. Psychotic experiences and their significance. World Psychiatry 2016;15:130-1.
9. Schultze-Lutter F, Ruhrmann S, Berning J. Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr Bull 2010;36:182-91.
10. Yung AR, Nelson B, Baker K et al. Psychotic-like experiences in a community sample of adolescents: implications for the continuum model of psychosis and prediction of schizophrenia. Aust N Z J Psychiatry 2009;43:118-28.
11. Kaymaz N, Drukker M, Lieb R et al. Do subthreshold psychotic experiences predict clinical outcomes in unselected non-help-seeking population-based samples? A systematic review and meta-analysis, enriched with new results. Psychol Med 2012;42:2239-53.
12. Rössler W, Riecher-Rössler A, Angst J et al. Psychotic experiences in the general population: a twenty-year prospective community study. Schizophr Res 2007;92:1-14.
13. Wigman JT, van Winkel R, Raaijmakers QA et al. Evidence for a persistent, environment-dependent and deteriorating subtype of subclinical psychotic experiences: a 6-year longitudinal general population study. PsycholMed 2011;41:2317-29.
14. De Loore E, Gunther N, Drukker M et al. Persistence and outcome of auditory hallucinations in adolescence: a longitudinal general population study of 1800 individuals. Schizophr Res 2011;127:252-6.
15. Downs JM, Cullen AE, Barragan M et al. Persisting psychotic-like experiences are associated with both externalising and internalising psychopathology in a longitudinal general population child cohort. Schizophr Res 2013;144:99-104.
16. van Os J, Linscott RJ, Myin-Germeys I et al. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med 2009;39:179-95.
17. Dominguez MD, Saka MC, Lieb R et al. Early expression of negative/disorganized symptoms predicting psychotic experiences and subsequent clinical psychosis: a 10-year study. Am J Psychiatry 2010;167:1075-82.
18. Chapman LJ, Chapman JP, Kwapil TR et al. Putatively psychosis-prone subjects 10 years later. J Abnorm Psychol 1994;103:171-83.
19. Ericson M, Tuvblad C, Raine A et al. Heritability and longitudinal stability of schizotypal traits during adolescence. Behav Genet 2011;41:499-511.
20. Cannon TD, Cadenhead K, Cornblatt B et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008;65:28-37.
21. Calkins ME, Moore TM, Merikangas KR et al. The psychosis spectrum in a young U.S. community sample: findings from the Philadelphia Neurodevelopmental Cohort. World Psychiatry 2014;13:296-305.
22. Paksarian D, Merikangas KR, Calkins ME et al. Racial-ethnic disparities in empirically-derived subtypes of subclinical psychosis among a U.S. sample of youths. Schizophr Res 2016;170:205-10.
23. Gur RC, Calkins ME, Satterthwaite TD et al. Neurocognitive growth charting in psychosis spectrum youths. JAMA Psychiatry 2014;71:366-74.
24. Satterthwaite TD, Wolf DH, Calkins ME et al. Structural brain abnormalities in youth with psychosis spectrum symptoms. JAMA Psychiatry 2016;73:515-24.
25. Roalf DR, Quarmley M, Calkins ME et al. Temporal lobe volume decrements in psychosis spectrum youths. Schizophr Bull (in press).
26. Wolf DH, Satterthwaite TD, Calkins ME et al. Functional neuroimaging abnormalities in youth with psychosis spectrum symptoms. JAMA Psychiatry 2015;72:456-65.
27. Satterthwaite TD, Vandekar SN, Wolf DH et al. Connectome-wide network analysis of youth with Psychosis-Spectrum symptoms. Mol Psychiatry 2015;20:1508-15.
28. Shanmugan S, Wolf DH, Calkins ME et al. Common and dissociable mechanisms of executive system dysfunction across psychiatric disorders in youth. Am J Psychiatry 2016;173:517-26.
29. Calkins ME, Merikangas KR, Moore TM et al. The Philadelphia Neurodevelopmental Cohort: constructing a deep phenotyping collaborative. J Child Psychol Psychiatry 2015;56:1356-69.
30. Merikangas KR, Calkins ME, Burstein M et al. Comorbidity of physical and mental disorders in the neurodevelopmental genomics cohort study. Pediatrics 2015;135:e927-38.
31. Satterthwaite TD, Elliott MA, Ruparel K et al. Neuroimaging of the Philadelphia Neurodevelopmental Cohort. Neuroimage 2014;86:544-53.
32. Miller TJ, Cicchetti D, Markovich PJ et al. The SIPS screen: a brief self-report screen to detect the schizophrenia prodrome. Schizophr Res 2004;70(Suppl. 1):78.
33. Kobayashi H, Nemoto T, Koshikawa H et al. A self-reported instrument for prodromal symptoms of psychosis: testing the clinical validity of the PRIME Screen-Revised (PS-R) in a Japanese population. Schizophr Res 2008;106:356-62.
34. Kaufman J, Birmaher B, Brent D et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children – Present and Lifetime version (K-SADS-PL): Initial reliability and validity. J Am Acad Child Adolesc Psychiatry 1997;36:980-8.
35. McGlashan TH, Miller TJ, Woods SW et al. Structured Interview for Prodromal Syndromes, Version 4.0. New Haven: Prime Clinic Yale School of Medicine, 2003.
36. DeMars CE. A tutorial on interpreting bifactor model scores. Int J Testing 2013;13:354-78.
37. Bonifay W, Lane SP, Reise SP. Three concerns with applying a bifactor model as a structure of psychopathology. Clin Psychol Sci (in press).
38. Kim JO, Mueller CW. Factor analysis: statistical methods and practical issues. Newbury Park: Sage, 1978.
39. Krueger RF. The structure of common mental disorders. Arch Gen Psychiatry 1999;56:921-6.
40. Revelle W. psych: procedures for personality and psychological research. R package version 1.5.8. Evanston: Northwestern University, 2015.
41. Muthèn LK, Muthèn BO. Mplus user’s guide, 7th ed. Los Angeles: Muthèn & Muthèn, 2015. \
42. Wilkinson GS, Robertson GJ. Wide Range Achievement Test, 4th ed. Lutz: Psychological Assessment Resources, 2006.
43. Han C, McGue MK, Iacono WG. Lifetime tobacco, alcohol and other substance use in adolescent Minnesota twins: univariate and multivariate behavioral genetic analyses. Addiction 1999;94:981-93.
44. Scott JC, Wolf DH, Calkins ME et al. Cognitive functioning in adolescent and young adult cannabis users in the Philadelphia Neurodevelopmental Cohort. Submitted for publication.
45. Moore TM, Martin IK, Gur OM et al. Characterizing social environment’s association with neurocognition using census and crime data linked to the Philadelphia Neurodevelopmental Cohort. Psychol Med 2016;46:599-610.
46. First MB, Spitzer RL, Gibbon M et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. New York:Biometrics Research, New York State Psychiatric Institute, 2002.
47. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
48. Maxwell ME. Manual for the FIGS. Bethesda: Clinical Neurogenetics Branch, Intramural Research Program, National Institute for Mental Health, 1996.
49. Raine A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull 1991;17:555-64.
50. Calkins ME, Curtis CE, Grove WM et al. Multiple dimensions of schizotypy in first degree biological relatives of schizophrenia patients. Schizophr Bull 2004;30:317-25.
51. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995;57:289-300.
52. Carrion RE, Cornblatt BA, Burton CZ et al. Personalized prediction of psychosis: external validation of the NAPLS-2 psychosis risk calculator with the EDIPPP project. Am J Psychiatry 2016;173:989-96.
53. Asher L, Zammit S, Sullivan S et al. The relationship between psychotic symptoms and social functioning in a non-clinical population of 12 year olds. Schizophr Res 2013;150:404-9.
54. Yung AR, Buckby JA, Cotton SM et al. Psychotic-like experiences in nonpsychotic help-seekers: associations with distress, depression, and disability. Schizophr Bull 2006;32:352-9.
55. Salokangas RK, Heinimaa M, From T et al. Short-term functional outcome and premorbid adjustment in clinical high-risk patients. Results of the EPOS project. Eur Psychiatry 2014;29:371-80.
56. Piskulic D, Addington J, Auther A et al. Using the global functioning social and role scales in a first-episode sample. Early Interv Psychiatry 2011;5:219-23.
57. Cechnicki A, Cichocki L, Kalisz A et al. Duration of untreated psychosis (DUP) and the course of schizophrenia in a 20-year follow-up study. Psychiatry Res 2014;219:420-5.
58. Gottesman II. Schizophrenia genesis: the origins of madness. New York:Freeman, 1991.
59. Kelleher I, Keeley H, Corcoran P et al. Clinicopathological significance of psychotic experiences in non-psychotic young people: evidence from four population-based studies. Br J Psychiatry 2012;201:26-32.
60. Williams DR, Earl TR. Race and mental health – more questions than answers. Int J Epidemiol 2007;36:758-60.
61. Cicero DC, Martin EA, Becker TM et al. Correspondence between psychometric and clinical high risk for psychosis in an undergraduate population. Psychol Assess 2014;26:901-15.
62. Debbane M, Eliez S, Badoud D et al. Developing psychosis and its risk states through the lens of schizotypy. Schizophr Bull 2015;41(Suppl. 2):S396-407.
63. Daneault JG, Stip E, Refer OSG. Genealogy of instruments for prodrome evaluation of psychosis. Front Psychiatry 2013;4:25.
64. Kline E, Wilson C, Ereshefsky S et al. Psychosis risk screening in youth: a validation study of three self-report measures of attenuated psychosis symptoms. Schizophr Res 2012;141:72-7.
65. Kline E, Thompson E, Demro C et al. Longitudinal validation of psychosis risk screening tools. Schizophr Res 2015;165:116-22.
66. David AS. Why we need more debate on whether psychotic symptoms lie on a continuum with normality. Psychol Med 2010;40:1935-42.
67. Hanssen M, Bak M, Bijl R et al. The incidence and outcome of subclinical psychotic experiences in the general population. Br J Clin Psychol 2005;44(Pt. 2):181-91.